{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:50:49Z","timestamp":1776408649734,"version":"3.51.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2706100"],"award-info":[{"award-number":["2023YFC2706100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2024-2-2097"],"award-info":[{"award-number":["2024-2-2097"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2022-2Z-2099"],"award-info":[{"award-number":["2022-2Z-2099"]}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"crossref","award":["Z221100007422067"],"award-info":[{"award-number":["Z221100007422067"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06875-8","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T08:21:19Z","timestamp":1772439679000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing pediatric ITP therapy: a real-world study on plasma concentration-guided eltrombopag dosing"],"prefix":"10.1007","volume":"105","author":[{"given":"Jia","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyue","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"3","key":"6875_CR1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1055\/s-0039-1683416","volume":"39","author":"R Kohli","year":"2019","unstructured":"Kohli R, Chaturvedi S (2019) Epidemiology and clinical manifestations of immune thrombocytopenia. Hamostaseologie 39(3):238\u2013249","journal-title":"Hamostaseologie"},{"issue":"23","key":"6875_CR2","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM et al (2019) American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3(23):3829\u20133866 Blood advances 2020","journal-title":"Blood Adv"},{"issue":"22","key":"6875_CR3","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"M Drew Provan, Donald","year":"2019","unstructured":"Drew Provan, Donald M, Arnold et al (2019) Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3(22):3780\u20133817","journal-title":"Blood Adv"},{"issue":"6","key":"6875_CR4","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","volume":"104","author":"W Ghanima","year":"2019","unstructured":"Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB (2019) Thrombopoietin receptor agonists: ten years later. Haematologica 104(6):1112\u20131123","journal-title":"Haematologica"},{"issue":"8","key":"6875_CR5","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","volume":"2","author":"JB Bussel","year":"2015","unstructured":"Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS et al (2015) Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2(8):e315\u2013e325","journal-title":"Lancet Haematol"},{"issue":"10004","key":"6875_CR6","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","volume":"386","author":"JD Grainger","year":"2015","unstructured":"Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P et al (2015) Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 386(10004):1649\u20131658","journal-title":"Lancet"},{"issue":"8","key":"6875_CR7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1177\/1076029616663849","volume":"23","author":"AS Elgebaly","year":"2017","unstructured":"Elgebaly AS, Ashal GE, Elfil M, Menshawy A (2017) Tolerability and efficacy of Eltrombopag in chronic immune thrombocytopenia: metaanalysis of randomized controlled trials. Clin Appl Thromb Hemost 23(8):928\u2013937","journal-title":"Clin Appl Thromb Hemost"},{"issue":"6","key":"6875_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/2042098618769587","volume":"9","author":"JR Gonzalez-Porras","year":"2018","unstructured":"Gonzalez-Porras JR, Bastida JM (2018) Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety. Ther Adv Drug Saf 9(6):263\u2013285","journal-title":"Ther Adv Drug Saf"},{"issue":"8","key":"6875_CR9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s40265-016-0581-4","volume":"76","author":"CB Burness","year":"2016","unstructured":"Burness CB, Keating GM, Garnock-Jones KP (2016) Eltrombopag: a review in paediatric chronic immune thrombocytopenia. Drugs 76(8):869\u2013878","journal-title":"Drugs"},{"issue":"2","key":"6875_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/08880018.2017.1313918","volume":"34","author":"JD Grainger","year":"2017","unstructured":"Grainger JD, Thind S (2017) A practical guide to the use of Eltrombopag in children with chronic immune thrombocytopenia. Pediatr Hematol Oncol 34(2):73\u201389","journal-title":"Pediatr Hematol Oncol"},{"issue":"23","key":"6875_CR11","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N et al (2019) American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3(23):3829\u20133866","journal-title":"Blood Adv"},{"issue":"22","key":"6875_CR12","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"D Provan","year":"2019","unstructured":"Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T et al (2019) Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3(22):3780\u20133817","journal-title":"Blood Adv"},{"issue":"5","key":"6875_CR13","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1111\/bjh.19735","volume":"205","author":"S Dong","year":"2024","unstructured":"Dong S, Wang Z, Wang N et al (2024) Exploratory study on the individualized application of Eltrombopag in paediatric immune thrombocytopenia guided by therapeutic drug monitoring. Br J Haematol 205(5):1930\u20137937","journal-title":"Br J Haematol"},{"key":"6875_CR14","first-page":"1","volume":"00","author":"S Dong","year":"2024","unstructured":"Dong S, Cheng X, Wang Z et al (2024) Spotlight on eltrombopag concentration in pediatric immune thrombocytopenia: A single-center observational study in China. Pediatr Investig 00:1\u20139","journal-title":"Pediatr Investig"},{"key":"6875_CR15","doi-asserted-by":"crossref","unstructured":"Working Group of Chinese Guideline for the Diagnosis and Treatment of Childhood Primary Immune Thrombocytopenia; Subspecialty Group of Hematologic Diseases, Society of Pediatrics, Chinese Medical Association; Editorial Board, Chinese Journal of Pediatrics. Adapted guideline for the diagnosis and treatment of primary immune thrombocytopenia for Chinese children (2021) (2022) Pediatr Investig 6:63\u201374","DOI":"10.1002\/ped4.12305"},{"issue":"19","key":"6875_CR16","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1182\/bloodadvances.2020004110","volume":"5","author":"X CHENG","year":"2021","unstructured":"Cheng X, Fu L, Ma J et al (2021) Spotlight on Eltrombopag in pediatric ITP in china: a long-term observational study in real-world practice. Blood Adv 5(19):3799\u20133806","journal-title":"Blood Adv"},{"key":"6875_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jpba.2014.04.028","volume":"98","author":"R MADDELA","year":"2014","unstructured":"Maddela R, Gajula R, Pilli N R et al (2014) Liquid chromatography-tandem mass spectrometric assay for Eltrombopag in 50\u00b5L of human plasma: a Pharmacokinetic study. J Pharm Biomed Anal 98:68\u201373","journal-title":"J Pharm Biomed Anal"},{"issue":"11","key":"6875_CR18","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F RODEGHIERO","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386\u20132393","journal-title":"Blood"},{"key":"6875_CR19","doi-asserted-by":"publisher","first-page":"1597641","DOI":"10.3389\/fphar.2025.1597641","volume":"16","author":"N WANG","year":"2025","unstructured":"Wang N, Dong S et al (2025) The establishment of an expected concentration reference range for Eltrombopag in the individualized treatment of pediatric immune thrombocytopenia. Front Pharmacol 16:1597641","journal-title":"Front Pharmacol"},{"issue":"2","key":"6875_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05329.x","volume":"129","author":"C DAME","year":"2005","unstructured":"Dame C, Sutor AH (2005) Primary and secondary thrombocytosis in childhood. Br J Haematol 129(2):165\u2013177","journal-title":"Br J Haematol"},{"key":"6875_CR21","doi-asserted-by":"publisher","first-page":"205873841987212","DOI":"10.1177\/2058738419872120","volume":"33","author":"X CHENG","year":"2019","unstructured":"Cheng X, Yan K, Ma J et al (2019) Efficacy and safety of Eltrombopag in the treatment of severe chronic immune thrombocytopenia in children of china: A single-center observational study. Int J Immunopathol Pharmacol 33:2058738419872120","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"2","key":"6875_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/bjh.18842","volume":"202","author":"Z WANG","year":"2023","unstructured":"Wang Z, Wang L, Liu Y et al (2023) Sustained response off treatment in Eltrombopag for children with persistent\/chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China. Br J Haematol 202(2):422\u2013428","journal-title":"Br J Haematol"},{"issue":"3","key":"6875_CR23","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/bjh.19253","volume":"204","author":"Z WANG","year":"2024","unstructured":"Wang Z, Wang N, Juntao O et al (2024) Long-term Eltrombopag in children with chronic immune thrombocytopenia: A single-centre extended real-life observational study in China. Br J Haematol 204(3):1017\u20131023","journal-title":"Br J Haematol"},{"key":"6875_CR24","doi-asserted-by":"publisher","first-page":"1214308","DOI":"10.3389\/fmed.2023.1214308","volume":"10","author":"G Paola Giordano","year":"2023","unstructured":"Paola Giordano G, Lassandro et al (2023) Long term use of Eltrombopag in children with chronic immune thrombocytopenia: extended real life retrospective multicenter experience of the Italian association of pediatric hematology and oncology. Front Med 10:1214308","journal-title":"Front Med"},{"key":"6875_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3389\/fmed.2020.00066","volume":"7","author":"G Paola Giordano","year":"2020","unstructured":"Paola Giordano G, Lassandro et al (2020) Use of Eltrombopag in children with chronic immune thrombocytopenia (ITP): A real life retrospective multicenter experience of the Italian association of pediatric hematology and oncology (AIEOP). Front Med 7:66","journal-title":"Front Med"},{"issue":"1","key":"6875_CR26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1080\/16078454.2021.1992945","volume":"26","author":"S POGNA E A, MIDDLETON","year":"2021","unstructured":"Pogna E A, Middleton S, Nazir J et al (2021) Characterization and treatment of immune thrombocytopenia in europe: a qualitative observational study. Hematology 26(1):860\u2013869","journal-title":"Hematology"},{"issue":"4","key":"6875_CR27","doi-asserted-by":"publisher","first-page":"e0267342","DOI":"10.1371\/journal.pone.0267342","volume":"17","author":"A ROV\u00f3","year":"2022","unstructured":"Rov\u00f3 A, Cantoni N, Samii K et al (2022) Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: results from a questionnaire conducted in Switzerland, Austria, and Belgium. PLoS ONE 17(4):e0267342","journal-title":"PLoS ONE"},{"issue":"5","key":"6875_CR28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00277-022-04786-y","volume":"101","author":"N VIANELLI","year":"2022","unstructured":"Vianelli N, Auteri G, Buccisano F et al (2022) Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. Ann Hematol 101(5):963\u2013978","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06875-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06875-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06875-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:58:26Z","timestamp":1776405506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06875-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6875"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06875-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committees of Beijing Children\u2019s Hospital and was conducted in accordance with the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}